Abstract
High-dose arabinoside cytarabine is used as an effective regimen for post-remission acute leukemia and refractory leukemia treatment. Most commonly used regimen is 3 g/m2 IV over 1-3 h q12 h for a total of 8-12 doses. Major toxic effects associated with cytarabine are related to bone marrow, gastrointestinal tract, and nervous system. Acute cerebellar toxicity with ataxia and dysarthria is well-known adverse effect during high-dose cytarabine therapy. This case report describes about a patient with acute myeloid leukemia on high-dose cytarabine who developed ataxia and left-sided nystagmus as cerebellar toxicity. These symptoms persisted till 2 days after the termination of high-dose cytarabine the gradually improved with steroids. PatientÂ’s good response to methyl prednisolone illustrates immune-mediated mechanism of neurotoxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: National Journal of Physiology, Pharmacy and Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
